Definitive Healthcare First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St

Definitive Healthcare (NASDAQ:DH) First Quarter 2025 Results

Key Financial Results

  • Revenue: US$59.2m (down 6.8% from 1Q 2024).
  • Net loss: US$107.2m (loss widened by US$97.7m from 1Q 2024).
  • US$0.95 loss per share (further deteriorated from US$0.081 loss in 1Q 2024).
Our free stock report includes 1 warning sign investors should be aware of before investing in Definitive Healthcare. Read for free now.
NasdaqGS:DH Earnings and Revenue Growth May 10th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Definitive Healthcare Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 5.3%. Earnings per share (EPS) missed analyst estimates significantly.

Looking ahead, revenue is forecast to stay flat during the next 3 years compared to a 10% growth forecast for the Healthcare Services industry in the US.

Performance of the American Healthcare Services industry.

The company's shares are up 30% from a week ago.

Risk Analysis

Be aware that Definitive Healthcare is showing 1 warning sign in our investment analysis that you should know about...

Valuation is complex, but we're here to simplify it.

Discover if Definitive Healthcare might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.